Clinical Diagnostic Criteria for Gout
Gout is an acute monoarticular arthritis triggered by monosodium urate crystal deposition, classically affecting the first metatarsophalangeal joint (MTP joint—the base of the big toe). The acute inflammatory response produces severe pain, swelling, erythema, and warmth within hours of onset. While historically diagnosed by synovial fluid analysis and crystal identification under polarized light microscopy, clinical scoring systems can help identify cases requiring confirmatory testing.
Seven variables inform diagnostic likelihood:
- Sex: Gout predominantly affects men, particularly those aged 40–50 years, though postmenopausal women show increasing prevalence.
- Previous attacks: Recurrent episodes suggest a chronic urate disposition problem.
- Rapid onset: Most gouty attacks develop to peak severity within 24 hours.
- Joint erythema: The overlying skin often displays marked redness and warmth.
- MTP joint involvement: The first MTP joint is the most frequently affected site (podagra); involvement here substantially increases diagnostic confidence.
- Cardiovascular comorbidity: Hypertension and other cardiovascular diseases correlate with gout risk.
- Serum uric acid: Levels above 5.88 mg/dL (0.35 mmol/L) reflect hyperuricaemia, a prerequisite for crystal formation.
Gout Likelihood Scoring System
The diagnostic algorithm combines seven clinical and laboratory parameters, each weighted equally. Points accumulate as you answer yes to present features. The final score indicates the probability of gout within three risk categories:
Total Score = Sex + Previous Attack + Onset ≤24h + Joint Redness
+ MTP Involvement + Hypertension/CVD + Serum UA > 5.88 mg/dL
Sex— Male sex assigned at birth (yes = 1 point)Previous Attack— Prior episode of acute arthritis meeting gout criteria (yes = 1 point)Onset ≤24h— Symptoms reaching peak severity within 24 hours (yes = 1 point)Joint Redness— Erythema of the affected joint (yes = 1 point)MTP Involvement— First metatarsophalangeal joint affected (yes = 1 point)Hypertension/CVD— Known hypertension or ≥1 cardiovascular disease (yes = 1 point)Serum UA— Serum uric acid concentration exceeding 5.88 mg/dL or 0.35 mmol/L (yes = 1 point)
Interpreting Diagnostic Probability Tiers
The total score segregates patients into three probability bands, each with distinct clinical implications:
- Score ≤4 points (Gout unlikely): Diagnostic prevalence is approximately 2.2%. The clinical picture does not align with typical gout; alternative diagnoses such as pseudogout, septic arthritis, or other inflammatory arthropathies should be considered. Synovial fluid analysis is not urgently indicated unless other features raise suspicion.
- Score 4–7.5 points (Gout possible): Estimated prevalence is 31.2%. Gout cannot be excluded; confirmatory testing such as synovial fluid aspiration with polarized microscopy, ultrasound, or dual-energy computed tomography (DECT) is recommended before starting long-term urate-lowering therapy.
- Score >7.5 points (Gout very likely): Diagnostic prevalence exceeds 80%. The clinical presentation is highly compatible with gout. Definitive crystal analysis confirms the diagnosis, but empirical anti-inflammatory treatment may commence while awaiting results if clinical urgency exists.
Acute Gout Management and Pharmacotherapy
Management of acute and chronic gout differ substantially. Acute flares demand rapid anti-inflammatory suppression, whilst chronic management addresses the underlying hyperuricaemia to prevent recurrent attacks.
Acute flare treatment:
- Colchicine: Inhibits microtubule polymerisation, reducing neutrophil recruitment. Initial dose is 1.2 mg, followed by 0.6 mg one hour later. Gastrointestinal tolerance varies; dose reduction is prudent in renal or hepatic impairment.
- NSAIDs: Indomethacin, naproxen, or other inhibitors of cyclooxygenase provide rapid pain relief and inflammation reduction. Contraindicated in significant renal disease, heart failure, or concurrent anticoagulation.
- Corticosteroids: Reserved for patients intolerant of colchicine or NSAIDs. Doses are typically equivalent to 20–40 mg prednisone daily for 5–7 days, tapered thereafter.
Critical caution with allopurinol: Initiating allopurinol during an acute attack paradoxically worsens inflammation by mobilising urate crystals from tissue deposits into synovial fluid. Begin urate-lowering therapy only after the acute episode resolves, waiting a minimum of two to four weeks. Concurrent colchicine or NSAIDs provide prophylaxis against flares during initiation.
Essential Diagnostic and Management Pitfalls
Recognise common missteps that delay diagnosis or compromise treatment outcomes.
- Normal uric acid during acute flare — Serum uric acid can remain low or normal during an active gout attack due to rapid incorporation into crystals and transient renal handling changes. Absence of hyperuricaemia does not exclude gout; 11–49% of patients experience acute attacks with serum levels below 5.88 mg/dL. Do not rely on uric acid levels alone for diagnostic exclusion.
- Premature allopurinol initiation — Starting allopurinol within days of an acute attack frequently precipitates severe worsening or a new flare. The abrupt drop in serum uric acid mobilises stored crystals from joints and subcutaneous deposits into synovial spaces. Always wait 2–4 weeks post-flare resolution before commencing xanthine oxidase inhibitors or other urate-lowering agents.
- Inadequate fluid intake during acute episodes — Patients often curtail fluid intake due to pain and immobility during acute gout. Dehydration concentrates serum uric acid and perpetuates crystal formation. Encourage consumption of at least 2–3 litres of water daily during and after flares. Avoid diuretics unless clinically necessary for other conditions.
- Overlooking secondary causes of hyperuricaemia — High alcohol intake (especially beer and spirits), excessive consumption of red meat, organ meats, seafood, and high-fructose beverages all elevate uric acid. Additionally, certain haematological malignancies, chronic kidney disease, and medications (diuretics, low-dose aspirin) contribute to hyperuricaemia. Address modifiable risk factors to reduce flare frequency independent of pharmacotherapy.